After triumphing over Novartis’ Cosentyx in a 2020 psoriasis study, Skyrizi has dished out another serving of competitor-busting data. This time, the AbbVie and Boehringer Ingelheim-partnered biologic ...
A big question hanging over AbbVie CEO Richard Gonzalez is whether he can lead the Illinois pharma safely through the patent cliff of its revenue cornerstone Humira. By the look of 2020’s results, ...
AbbVie's beat Wall Street's estimates for its top- and bottom-lines in its latest quarter, boosted by sales of Skyrizi and Rinvoq. The North Chicago, Ill., drugmaker said it logged earnings of $938 ...
AbbVie Inc. (NYSE:ABBV) ranks among the best low volatility stocks to buy according to analysts. Ahead of the company’s second-quarter earnings report, JPMorgan reaffirmed its Overweight rating and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback